Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Valproate is the first line therapy in primary generalized seizures. The applied drug
contains sodium valproate in sustained release minitablets. As a multiple unit dosage form
these can be easily swallowed and taken independent from meals.
A simple dosage scheme like valproate sustained release minitablets once daily in the evening
should improve the compliance and likely the seizure situation of the patients. The data of
this non interventional trial were directly extracted from the physician's electronic patient
database. The observational period was 7 weeks compared to a retrospective period 7 weeks
before start of the study.